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Introduction
Sarcoidosis is a multisystem granulomatous disorder of unknown cause that may involve any 
organ. Pulmonary involvement predominates as well as affection of the intrathoracic lymph nodes, 
eyes and skin; however it may affect any organ [1]. Extrathoracic manifestation is common and 
seen in more than 30% of patients, typically in combination with thoracic involvement. Sarcoidosis 
occurs at all ages, however with the incidence peaking at 20-39 years.
Systemic symptoms are weight loss, fatigue and night sweats but most patients present with 
cough and dyspnea because of pulmonary involvement. The diagnosis of sarcoidosis is based on 
clinical and radiological findings as well as histological findings of non-caseating epithelioid-cell 
granulomas. Other causes of granulomas must be ruled out. Chest radiography and computed 
tomography (CT) are used as routine diagnostic procedures in the evaluation of pulmonary 
sarcoidosis but they are unable to detect active inflammation.
18F-fluorodeoxyglucose positron-emission tomography (18F-FDG PET)/CT has shown useful in 
assessing the extent of organ involvement and in suggesting the organs that might be candidates 
for diagnostic biopsy [2]. Furthermore, 18F-FDG PET/CT seems to contribute to a better evaluation 
of the extrapulmonary involvement and it may identify occult granulomatous lesions that are not 
detected by physical examination, conventional thoracic radiography or CT [3,4]. Additionally, the 
18F-FDG PET/CT has been compared to 67Ga-scintigraphy in patients with sarcoidosis illustrating a 
superior sensitivity, especially in depicting sites of extrathoracic involvement [5].
Here we report a case of sarcoidosis detected by 18F-FDG PET/CT.
Case Presentation
A 29-year old man with a history of bilateral enlargement of the parotid glands, alternating fever, 
discrete dyspnea, and fatigue for several months was admitted to the hospital. Before admission, the 
patient had been examined by an otorhinolaryngologist and a fine needle biopsy from the parotid 
gland was conducted, demonstrating granulomas, indicative of sarcoidosis. The patient had felt 
enlargement of the inguinal lymph nodes but had otherwise no other discomforts. Due to suspicion 
of sarcoidosis, an 18F-FDG PET/CT was conducted to visualize the extent of organ involvement. 
The 18F-FDG PET/CT revealed significantly increased 18F-FDG uptake in bilateral enlarged parotid 
glands (Figure 1A-D) and in bilateral mediastinal and hilar lymph nodes, predominantly right 
paratracheal adenopathy (Figure 1E-G). No enlargement or increased 18F-FDG uptake was observed 
in the inguinal lymph nodes. Measurement of the serum angiotensin-converting-enzyme (ACE) 
demonstrated highly elevated level (166 U/l) (normal upper limit < 115 U/l). 
The 18F-FDG PET/CT findings, elevated level of serum ACE, and histopathological examination 
of parotid gland biopsy with non-caseating epithelioid-cell granulomas confirmed the diagnosis of 
sarcoidosis.
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Abstract
Sarcoidosis is a multisystem granulomatous disease of unknown cause that primarily involves the 
lungs. Extrapulmonary sarcoidosis is seen in more than 30% of patients. We report a case of a 
29-year old man presenting with bilateral enlargement of the parotid glands combined with fever, 
discrete dyspnea, and fatigue. Histopathology from the parotid gland indicated sarcoidosis. An 
18F-FDG PET/CT performed to visualize the organ extent demonstrated increased 18F-FDG uptake 
in the parotid glands and in bilateral mediastinal and hilar lymph nodes. The patient was diagnosed 
with sarcoidosis.
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As the patient’s symptoms were regressing, no treatment was 
initiated.
Discussion
In 1990 Sulavik and colleagues described increased symmetrical 
lacrimal gland and parotid gland 67Ga-citrate uptake combined 
with normal accumulation of the radionuclide in the nasopharynx 
(“panda” appearance) in 79% of sarcoidosis patients [6]. Furthermore, 
a distinctive intrathoracic lymph node 67Ga -uptake pattern was 
observed, resembling the Greek letter lambda (λ). The simultaneous 
"lambda" and "panda" patterns were observed only in sarcoidosis 
patients and this was considered highly specific for sarcoidosis [6]. 
Therefore, it has been argued that the combination of the "lambda" 
and "panda" sign may obviate a histopathological examination. 
Enlargement of the parotid glands is rarely seen in patients with 
sarcoidosis (~6%) [7].
The appearance of hypermetabolic intrathoracic 
lymphadenopathy detected by 18F-FDG PET/CT in patients with 
sarcoidosis is comparable to the "lambda" sign on the gallium 
scintigraphy as well as the bilateral involvement of the parotid and 
lacrimal glands with high 18F-FDG uptake, resembling the "panda" 
sign [8]. The typical "panda" appearance is however partially obscured 
because of the high physiological 18F-FDG uptake of the brain. In our 
patient the "lambda" and "panda" signs coexisted on the 18F-FDG 
PET/CT although involvement of the lacrimal glands could not be 
visualized.
18F-FDG PET/CT is increasingly used in the diagnostic work-
up of pulmonary and mediastinal tumors that are suspected to be 
malignant. However, sarcoid lesions can demonstrate high 18F-FDG 
uptake mimicking malignant processes such as lymphoma or lymph 
node metastases. Irrespective of the combination of the “lambda” and 
“panda” signs detected by 18F-FDG PET, histological confirmation 
should be mandatory.
In active sarcoidosis, a significant increased metabolism in 
the active lesions can be detected by an increased 18F-FDG uptake. 
However, after immunosuppressive therapy or spontaneous 
regression, the metabolism of the lesions may decrease [4,9,10], 
probably prior to morphological changes. Thus, 18F-FDG PET/CT 
may be a valuable adjunct to the clinical examination in monitoring 
the response to therapy. 
Although the serum level of ACE is elevated in up to 60% of 
sarcoidosis patients, it is never diagnostic since elevation can be seen 
in other diseases [7]. It may however decrease after corticosteroid 
treatment or spontaneous improvement [1]. In this patient no 
treatment was initiated as spontaneous regression was observed. 
Conclusion
18F-FDG PET/CT is valuable in demonstrating active lesions 
of sarcoidosis, both thoracic and extrathoracic involvement. 
Furthermore, 18F-FDG PET/CT might be useful in monitoring 
treatment response in patients with sarcoidosis; however, costs and 
radiation expose should always be taken into account.
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